The Defense Health Agency has issued an amendment to the solicitation HT9402-24-Q-9404, aimed at updating a Request for Quotation related to the addition of two newly approved drugs. The drugs included in this modification are: Aqneursa, categorized as a Neurological Agents Miscellaneous, and Cobenfy, classified as an Atypical Antipsychotic Agent. Accompanying the announcement are the price lists for both medications. The document reaffirms that all other terms and conditions remain unchanged. This amendment reflects the ongoing efforts to ensure that the healthcare options provided to service members are up-to-date with the latest pharmaceutical advancements, supporting the commitment to enhance the quality of care.

The document outlines the process for the formulary placement of newly approved innovator drugs under the TRICARE Pharmacy Benefits Program, following the Final Rule published on July 27, 2015. It establishes that the Pharmacy and Therapeutics (P&T) Committee has up to 120 days to evaluate and recommend tier placements for FDA-approved innovator drugs, which include various types of new molecular entities, active ingredients, dosage forms, and drug combinations. Newly approved drugs will initially have a pending status and available under non-formulary terms, while pending drugs will be reviewed and classified based on clinical and cost-effectiveness. The Department of Defense (DoD) will solicit pricing concessions from manufacturers in three windows leading up to quarterly meetings. Drugs receiving a Tier 3 designation are not available at Military Treatment Facilities (MTFs) unless necessitated by medical circumstances. The document emphasizes that clinical presentations from innovator drug manufacturers will not be considered due to the volume of drugs being reviewed quarterly. This process demonstrates the DoD's adherence to cost-effective health care while ensuring medication accessibility for service members through established guidelines.

The Price Appendix FAQ outlines the procedures for submitting drug price quotes for formulary consideration by the Pharmacy and Therapeutics (P&T) committee. It emphasizes the importance of reviewing the Formulary Notes for clarity on decision-making processes. There are three main categories for the quotes: BPA (Business Pricing Agreement), ADP (Average Discount Pricing)—both for non-FAMP and WAC discounts. Participants are instructed to fill out designated yellow cells in provided tables for up to 10 National Drug Codes (NDCs), with automatic calculations for pricing metrics to facilitate submission. Specific conditions such as indicating no quote submission will be highlighted in red for clarity. Guidelines also include steps for additional NDC submissions and recommendations for contacting Points of Contact (POCs) for assistance with the quoting process. This comprehensive document ensures accurate and efficient participation in price quotation, aligning with federal contracting and procurement protocols. Overall, the FAQ serves as a vital resource for stakeholders engaged in federal grant applications and state/local RFP processes, ensuring compliance and clarity in submissions.

The document outlines the upcoming Review and Recommendations from the DoD’s Pharmacy and Therapeutics (P&T) Committee meeting scheduled for November 6-7, 2024, focused on Neurological Agents Miscellaneous. It emphasizes the process for manufacturers to submit quotes due by October 16, 2024, for several newly approved drugs. The document details various drug entries, including their National Drug Code (NDC) numbers, form categories, and pricing specifics, indicating a standard procedure with consistent pricing across various package sizes. Additionally, it emphasizes the possibility of prior authorization for certain medications, and notes may include mechanisms to encourage the use of higher-value products while discouraging lower-value options. The committee may recommend preferential treatment for certain drugs, potentially treating specific non-generic agents as generics for cost-sharing purposes. The document serves as a guideline for manufacturers regarding submissions while ensuring adherence to DoD formulary policies, highlighting the critical intersection of drug pricing, accessibility for military personnel, and the regulatory landscape for pharmaceutical procurement in government contexts.

The document outlines information related to the Department of Defense's Uniform Formulary class of antipsychotic agents, specifically focusing on atypical agents. It details the upcoming Pharmacy and Therapeutics (P&T) Committee Meeting scheduled for November 6-7, 2024, during which newly approved drugs will be reviewed. Quotes for these drugs are due by October 16, 2024. The document emphasizes the importance of submitting completed quotes and includes potential drug scenarios, pricing structures, and conditions relevant to the TRICARE pharmacy benefit program. It also mentions the possibility of forming blanket purchase agreements and additional discount programs for the agents discussed. Notably, the P&T Committee may recommend preferential treatment or exclusion of certain drugs based on their value, aiming to promote high-value products while managing costs effectively. Overall, the document serves to inform manufacturers and stakeholders about key deadlines and the evaluation criteria for drug inclusion in the formulary, reflecting the government's efforts to maintain an efficient healthcare system for military personnel.

The Department of Defense (DOD) Uniform Formulary Class for Ophthalmic medications, specifically within the subclass of corticosteroids, is slated for a Pharmacy and Therapeutics (P&T) Committee meeting on November 6-7, 2024. Quotes for newly approved drugs in this category are due by October 16, 2024. The document outlines multiple scenarios regarding the submission of quotes, indicating that for several National Drug Code (NDC) entries, both uniform and non-formulary drugs currently have no quoted prices. It emphasizes the process for manufacturers, highlighting that submitted quotes must include fully executed signature pages. The P&T Committee may recommend prior authorization, consider special reimbursement methods, and determine the cost-sharing statuses of these medications, including possible exclusion from the TRICARE pharmacy benefit program. Furthermore, the document includes additional considerations for retail refund scenarios based on tier classifications of the drugs, aiming to facilitate access to high-value products while discouraging lower-value options. This document plays a pivotal role in ensuring the efficient procurement and management of essential medications for military health facilities.

The document outlines the Department of Defense's (DoD) Uniform Formulary Class for the treatment of atopy, which is scheduled for a Pharmacy and Therapeutics (P&T) Committee Meeting on November 6-7, 2024. Quotes for newly approved drugs, categorized under atopy, are due by October 16, 2024. It details various drug scenarios encompassing both formulary and non-formulary classifications without any provided quotes. The report specifies that prior authorization may be required, and certain high-value products may be favored over low-value ones in reimbursement considerations. The P&T Committee may also suggest additional reimbursement incentives or exclusion from the TRICARE pharmacy benefit program. Manufacturers are reminded to submit signed documents along with their quotes and to ensure standard pricing across different package sizes. Essentially, the document serves as a formal notification and guideline for pharmaceutical manufacturers intending to participate in the bidding process for drugs aimed at treating atopy, stressing the importance of compliance with federal regulations while offering various pricing and formulary considerations to optimize healthcare outcomes for military beneficiaries.

The document outlines a government Request for Proposal (RFP) regarding the procurement of contraceptive agents as part of the Department of Defense (DoD) Uniform Formulary for an upcoming Pharmacy and Therapeutics (P&T) Committee Meeting scheduled for November 6-7, 2024. Quotes for the newly approved drugs are due by October 16, 2024. The document is structured into sections describing each drug under consideration, including National Drug Code (NDC) numbers, dosage forms, package sizes, and pricing details where quotes are required. It emphasizes the need for manufacturers to submit fully executed signature pages alongside their quote submissions. Additional notes specify that prior authorization may apply for certain medications, and that pricing structures will be uniformly applied across different package sizes. There are references to discount programs and refund calculations tied to the TRICARE retail pricing mechanisms, which are important for reimbursement and cost-effectiveness analysis. The focus is on ensuring that all parties involved in the pharmaceutical supply chain meet regulatory and contractual obligations while accommodating the specific needs of military treatment facilities.

The document outlines the Department of Defense (DOD) Uniform Formulary's considerations for newly approved oncological agents, specifically slated for discussion in the Pharmacy and Therapeutics (P&T) Committee meeting on November 6-7, 2024. It highlights a series of blanket purchase agreements with quotes due by October 16, 2024. Each agreement identifies National Drug Code (NDC) numbers, dosage forms, package sizes, and pricing details for both formulary and non-formulary drugs. Key points emphasize the protocols for prior authorization, pricing strategies, and potential preferential status for non-generic medications. The document includes detailed conditions, scenarios for pricing adjustments, and a systematic approach to evaluating the formulary status based on drug pricing and market considerations. Providers are reminded to include fully executed signature pages with their quote submissions. Overall, the document serves as a call for quotes from vendors for new oncology drugs and outlines the requirements and procedures associated with this procurement process, reflecting the DOD's strategy to ensure high-value treatment options for TRICARE beneficiaries while managing pharmaceutical costs effectively.

The document outlines key information regarding the Department of Defense (DOD) Uniform Formulary Class focusing on ADHD agents, specifically non-stimulants. A Pharmacy and Therapeutics (P&T) Committee meeting is scheduled for November 6-7, 2024, with quotes for new drugs due by October 16, 2024. The document includes various new drugs that are being evaluated for inclusion in the formulary, detailing conditions for submission, including NDC numbers, drug names, strengths, and package sizes. Notably, it mentions that the P&T Committee may offer preferential status for certain agents based on cost-sharing criteria or recommend their exclusion from the TRICARE pharmacy benefit program. Manufacturers are reminded to submit complete documentation along with their quotes. Additionally, the document outlines a mechanism for evaluating pricing under the TRICARE retail refund program, indicating that prior authorization may be required for certain agents. The overall purpose is to facilitate the procurement of pharmaceuticals for the DOD's healthcare system while ensuring that cost-effective and high-value products are prioritized through the formulary review process.

The document outlines the upcoming P&T Committee Meeting for the Department of Defense (DoD) regarding the inclusion of newly approved antihypertensive agents, specifically endothelin receptor antagonists, into the DoD Uniform Formulary. The meeting is scheduled for November 6-7, 2024, with quotes for these agents due by October 16, 2024. The document specifies that the drugs will be classified under various formulary tiers, including Tiers 2 and 3 for different National Drug Codes (NDCs). It also notes that prior authorization may be required, and some agents may be designated as non-step-preferred if no quotes are submitted or selected. Manufacturers are reminded to include fully executed signature pages with their quotes. Additionally, the document indicates a focus on evaluating agents for reimbursement strategies that promote high-value products and discourage low-value options. The potential for preferential treatment for non-generic products may also be discussed, emphasizing the DoD's commitment to optimizing pharmaceutical spending while maintaining patient health standards. The meeting aims to facilitate strategic decision-making on pharmaceutical inclusions for military treatment facilities and the TRICARE pharmacy benefit program.

The Department of Defense (DoD) is preparing for a Pharmacy and Therapeutics (P&T) Committee meeting scheduled for November 6-7, 2024, focusing on the review of Osteoporosis Agents, specifically PTH Analogs. Quotes for newly approved drugs are required by October 16, 2024. The document outlines various drug entries classified as either Uniform or Non-Formulary, indicating that no quotes have been received for these drugs. Additionally, the document includes information on pricing structures, including details about Wholesale Acquisition Costs (WAC) and methods for calculating refunds under the TRICARE retail program. The P&T Committee may recommend special reimbursement methods to promote the use of high-value products while discouraging low-value options. A prior authorization process may be implemented for new patients requiring a trial of preferred agents prior to approval for non-preferred options. This document serves as an invitation for pharmaceutical manufacturers to submit quotes while stressing the importance of compliance with requirements and timelines established by the DoD. Overall, it highlights the critical role of formulary management in optimizing drug utilization and cost-effectiveness within the military healthcare system.

The Department of Defense (DOD) is requesting quotations for pharmaceutical agents to establish a Uniform Formulary (UF) for the Military Health System (MHS). This document outlines the quote submission process for manufacturers, emphasizing the importance of cost-effectiveness and clinical effectiveness of the agents being proposed. The Pharmacy and Therapeutics (P&T) Committee evaluates these agents based on their therapeutic class and determines their cost-share tier classification, which can range from generic (Tier 1) to non-formulary (Tier 3). Manufacturers are required to submit price quotes through Blanket Purchase Agreements (BPA) for Military Treatment Facilities (MTF) and the TRICARE Mail Order Pharmacy (TMOP), and Additional Discount Program (ADP) quotes for retail network pharmacies. The document also details specific submission steps, deadlines, and required documentation for each type of quote. A pre-quotation teleconference will allow potential companies to ask questions, with an emphasis on adherence to federal pricing standards and regulations. The guidelines also explain the evaluation criteria used by the DOD P&T Committee, including consideration for a new drug's advantages and its prior use, ensuring comprehensive analysis before any pharmaceutical agent is admitted to the Uniform Formulary. This process reflects DOD's commitment to procuring effective and economically efficient pharmaceuticals for military members and their families.